|
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
|
31 August 2021 |
|
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrates improved immune response and protection in preclinical study
|
18 August 2021 |
|
GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
|
30 July 2021 |
|
GSK and Alector announce global collaboration in immuno-neurology
|
02 July 2021 |
|
GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
|
21 June 2021 |
|
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
|
27 May 2021 |
|
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
|
15 April 2021 |
|
GSK to support manufacture of Novavax' COVID-19 vaccine
|
30 March 2021 |
|
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
|
24 February 2021 |
|
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
|
19 February 2021 |